initiation in a French nationwide representative cohort. Methods: A retrospective cohort study was conducted on a random sample of *600,000 beneficiaries registered in the French national health insurance database. Newly insulin treated T2DM patients were selected. Persistence was defined as remaining on insulin without discontinuation (defined over a 6 or a 12-month period). 
INTRODUCTION
Insulin treatment has historically been the mainstay of the management of type 1 diabetes mellitus (T1DM), but has only more recently come to occupy a central role in the management of type 2 diabetes mellitus (T2DM). This change has partly relied on the introduction of modified long-acting insulins (basal insulins) as well as blood glucose control devices that make insulin therapy simpler for the patient. In particular, insulin therapy is recommended in patients who fail to achieve glycemic control with combinations of oral antidiabetic drugs (OADs) [1] [2] [3] . In USA, about 33.5% of patients aged 18 years or older with prescribed treatment for diabetes are receiving insulin therapy [4] . In France, it has been estimated that only 25% of the three million patients with prescribed treatment for diabetes are treated with insulin [5] .
Both T2DM and T1DM patients have difficulties managing their antidiabetic medications including insulin [6] . Among T2DM patients, this often results in low treatment persistence, which has been defined as the proportion of patients who remained on treatment for a specific time or the duration of time from initiation to discontinuation of therapy.
Treatment adherence and persistence are important factors that influence the effectiveness of antidiabetic medication [7] [8] [9] [10] [11] and there is considerable evidence that adherence to and persistence with OADs remains suboptimal [11, 12] .
A number of studies have been performed to evaluate persistence in patients prescribed OADs, but less in patients receiving insulin therapy, although renouncement to insulin leaves the patients with limited choice of anti-diabetes therapy [13] [14] [15] [16] [17] . Most of these studies were conducted in the US. 
Selection of the Study Patients
The study aimed to identify all patients with diabetes and treated with insulin documented in the EGB database during the study period. In a first step, these patients were identified by three prescription claims for antidiabetic medication (including insulin products; two when large packaging was used) within two consecutive years. Only adult patients C18 years of age were included. A decision tree was used to distinguish patients with T1DM from those with T2DM [20] (Fig. 1 ). This was based on the identification of hospitalizations with diabetes as an identified diagnosis (PD, RD or AD), the identification of long-standing condition status for diabetes through the associated ICD-10 code (E10 for T1DM and E11 for T2DM), as well as insulin treatment history.
For the purposes of this study, only patients with T2DM (as defined by the decision tree) and starting insulin therapy (index insulin prescription) during the two study periods described above were retained for analysis.
Patients fulfilling the selection criteria were divided into three groups: patients delivered basal insulins only, patients delivered basal and rapid acting insulins, and patients under other insulin treatment regimens.
Data Collection
For each participant, data were retrieved from the EGB database relating to the age and gender of the patient, antidiabetic medication prescribed during the study period and during the year preceding initiation of insulin treatment and the type of physician prescribing insulin.
Longitudinal data on prescription of antidiabetic medication was retrieved covering the period between the initial insulin prescription and the end of the study period 
Initiation of Insulin Prescription
Insulin therapy with basal insulin only was mainly initiated by a general practitioner, whereas other insulin regimens were principally initiated by a hospital physician.
During the previous 6 months, 18 discontinuation is set as a 12 months interruption of insulin treatment, 24.9% of patients had discontinued insulin therapy within 1 year after its initiation (excluding deaths) ( Table 3) .
Persistence was better in the patients starting a treatment with a basal insulin only and worse in those starting other insulin treatment regimens ( Table 3 ). The median treatment duration was longest in patients' prescribed basal insulin only (17 months) and lowest in those prescribed another insulin regimen (Fig. 4) .
DISCUSSION
This study was designed to document the maintenance of insulin therapy in patients with T2DM after initiation in a representative sample of the French national insurance claims database. The main finding was that excluding deaths and defining discontinuation in a rather conservative way (at least 12 months without any reimbursement of insulin therapy) around 25% of patients starting insulin therapy had discontinued treatment within a year. This high rate is of concern as the mean age of the patients is over 65, and the decision of insulin initiation suggests a need. This observation is somewhat counter-intuitive because insulin therapy is usually a late, often delayed, option in patients with T2DM; indeed, the mean age of the participants to this study is over 65.
However, the 1-year persistence rates in our study are consistent with the results from the claims studies conducted among
North-American patients with diabetes starting injectable therapy, despite differences in the health insurance systems. In a study of the General Electric Centricity electronic medical record database between November 2004 and August 2010, Wu et al. [21] found that about a third of patients (32.9%) initiating an insulin therapy discontinued (defined as a 90-day gap) the index insulin within 12 months from initiation. Wei et al. [15] performed a pooled analysis of three prescription claims studies performed in the USA and reported a were persistent at 1 year was only 28.7%. In Japan, 22% of patients discontinued basal insulin in the year after initiation according to a reimbursement claim base [24] . In Germany, the discontinuation rate was also around 20%
and 30% after 1 year with glargine and NPH, respectively [16] . In this work, in France, a persistence rate of 75.0% after initiation of insulin (and 82% when the insulin 
